Quest Diagnostics (DGX) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $25.22B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | James E. Davis |
| IPO Date | 1996-12-17 | CAGR | 6.85% |
| Employees | 57,000 | Website | www.questdiagnostics.com |
| Div. Yield | 0.3% | Payout Ratio | 35% |
| Buy Back Yield | 0.37% | Total Yield | 0.67% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $31.77B | P/E | 22.47 | Forward P/E | 19.12 | PEG | 1.56 |
| P/S | 10.71 | P/B | 16.36 | P/CF | 65.11 | P/FCF | 91.45 |
| Sales | $11.28B | Sales 1Y | 11.03% | Sales 3Y | 17.44% | Sales 5Y | 9.12% |
| EPS | $10.14 | EPS 1Y | 14.27% | EPS 3Y | 33.68% | EPS 5Y | -31.28% |
| Sales QoQ | 3.17% | EPS QoQ | 2.75% | Sales QoQ Avg | 2.23% | EPS QoQ Avg | 4.61% |
| Gross Margin | 33.23% | Operating Margin | 14.31% | Profit Margin | 9.08% | ROCE | 11.13% |
| ROA | 6% | ROE | 14% | Altman Z Score | 3.57 | Piotroski Score | 7 |
| Current Ratio | 1.18 | Quick Ratio | 1.08 | Cash Ratio | 0.18 | Op. CF Ratio | 0.13 |
| Debt/Equity | 0.95 | Debt/Assets | 0.42 | Lt Debt/Equity | 0.86 | Lt Debt/Cap. | 0.44 |
| Intrst Cov. | 6.09 | Inventory Turnover | 33.47 | Asset Turnover | 0.68 | Receivables Turnover | 7.11 |
| Enterprise Value | $31.77B | P/E Ratio | 22.47 |
| Forward P/E | 19.12 | PEG Ratio | 1.56 |
| P/S Ratio | 10.71 | P/B Ratio | 16.36 |
| P/CF Ratio | 65.11 | P/FCF Ratio | 91.45 |
| EPS | $10.14 | EPS Growth 1Y | 14.27% |
| EPS Growth 3Y | 33.68% | EPS Growth 5Y | -31.28% |
| Revenue Growth 1Y | 11.03% | Gross Margin | 0.33% |
| Operating Margin | 0.14% | Profit Margin | 0.09% |
| ROE | 0.14% | ROA | 0.06% |
| ROCE | 0.11% | Current Ratio | 1.18 |
| Quick Ratio | 1.08 | Cash Ratio | 0.18 |
| Debt/Equity | 0.95 | Interest Coverage | 6.09 |
| Altman Z Score | 3.57 | Piotroski Score | 7 |
Quest Diagnostics (DGX) valuation & financials
Quest Diagnostics (DGX) has a market capitalization of $25.22B and trades at a price-to-earnings ratio of 22.5. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Quest Diagnostics's revenue grew +11.0% over the last year.
Quest Diagnostics's next earnings report is scheduled for October 20, 2026 before market open; analysts estimate EPS of $2.81.
Quest Diagnostics (DGX) — frequently asked questions
When does Quest Diagnostics (DGX) report earnings next?
Quest Diagnostics is expected to report earnings on October 20, 2026 before market open. Analysts estimate EPS of $2.81.
What is Quest Diagnostics's market cap?
Quest Diagnostics (DGX) has a market capitalization of $25.22B.
What is DGX's P/E ratio?
Quest Diagnostics trades at a price-to-earnings ratio of 22.5, with trailing twelve-month EPS of $10.14.
How fast is Quest Diagnostics growing?
Quest Diagnostics's revenue grew +11.0% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)